Actinium-225-macropa-pelgifatamab (BAY 3546828) / Bayer, Lantheus - LARVOL DELTA

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - P1 | N=232 | Recruiting | Sponsor: Bayer | N=140 ➔ 232

Enrollment change • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Redistribution of the daughter radionuclides generated from 225Ac-pelgifatamab and their contribution to therapeutic efficacy in LNCaP/KUCaP prostate cancer xenograft models (EANM 2024) - "Both bismuth-213 and francium-221, the alpha-emitting daughter radionuclides of actinium-225, are mostly retained in the tumour. Only minor amounts of the daughter radionuclides generated in the blood were redistributed to the kidneys."

Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - P1 | N=140 | Not yet recruiting | Sponsor: Bayer

Metastases • New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor